Maze Therapeutics to Participate in the 2023 Jefferies Healthcare Conference SOUTH SAN FRANCISCO, CA., June 1, 2023 –Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that management will present a company overview at the 2023…
Maze Therapeutics to Participate in the 2023 Jefferies Healthcare Conference SOUTH SAN FRANCISCO, CA., June 1, 2023 –Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that management will present a company overview at the 2023…
Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease MZE001 was Well-tolerated and Reduced Glycogen Accumulation in Blood Cells and Muscle in Healthy Volunteers Maze to Receive…
Data Further Supports Proof of Mechanism for MZE001, an Oral Substrate Reduction Therapy, with approximately 60% Reduction in Muscle Glycogen in Healthy Volunteers Non-invasive Biomarker Developed by Maze to Measure Glycogen Levels Suggests Approximately 1:1 Correlation Between PBMC Blood Test…
Maze Therapeutics Announces Positive Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease MZE001 Was Well Tolerated and Reduced Glycogen Accumulation in Blood Cells in Healthy Volunteers Phase 1 Results Support Advancement into…
Maze Therapeutics Announces Completion of Phase 1 First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease MZE001 was Well-Tolerated and Reduced Glycogen Accumulation in Blood Cells in Healthy Volunteers, Supporting Advancement into Phase 2 Clinical Trial SOUTH…
Maze Therapeutics Presents Preclinical Data Highlighting Potential of APOL1 Inhibitor Program as a Treatment for Chronic Kidney Disease Significant Reductions of Disease Manifestations in Proprietary Mouse Renal Model of APOL1-Mediated Kidney Disease Observed New Research Shows APOL1 p.N264K Variant Associated…
Maze Therapeutics Appoints Harold Bernstein, M.D., Ph.D., as President, Research and Development and Chief Medical Officer Eric Green, M.D., Ph.D., Promoted to Chief Scientific Officer SOUTH SAN FRANCISCO, CA., Oct. 12, 2022 – Maze Therapeutics, a company translating genetic insights…
Maze Therapeutics Appoints Sekar Kathiresan, M.D., to its Board of Directors SOUTH SAN FRANCISCO, CA., Sept. 22, 2022 – Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that Sekar Kathiresan, M.D., a Maze co-founder,…
Maze Therapeutics Announces FDA Orphan Drug Designation Granted to MZE001 for the Treatment of Pompe Disease SOUTH SAN FRANCISCO, CA., Aug. 31, 2022 – Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced that the…